APP
HAE icon

Avantax Planning Partners’s Haemonetics HAE Stock Holding History

Avantax Planning Partners’s Portfolio HAE Stock Details HAE Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2018
Q4 		– Sell
-29
Closed -$3K – 656
2018
Q3 		$3K Buy
+29
New +$3K ﹤0.01% 1254
2018
Q2 		– Sell
-29
Closed -$2K – 732
2018
Q1 		$2K Buy
+29
New +$1.99K ﹤0.01% 1598

Other funds holding HAE

BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
Wellington Management Group
Wellington Management Group Boston, Massachusetts $535B AUM 26.23% 1-Year Est. Return
Renaissance Technologies
Renaissance Technologies New York $63.9B AUM 45.56% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
JSP
Jackson Square Partners Larkspur, California $247M AUM 20.29% 1-Year Est. Return
Neuberger Berman Group
Neuberger Berman Group New York $131B AUM 28.36% 1-Year Est. Return
Capital Research Global Investors
Capital Research Global Investors Los Angeles, California $645B AUM 30.41% 1-Year Est. Return
HM
HealthCor Management New York $109M AUM 10.64% 1-Year Est. Return
Dimensional Fund Advisors
Dimensional Fund Advisors Austin, Texas $481B AUM 30.42% 1-Year Est. Return

Avantax Planning Partners's HAE Position: Q4 2018 in Review

Avantax Planning Partners sold out of Haemonetics (HAE) in Q4 2018, closing a stake of 29 shares — an estimated $3K sold.

Avantax Planning Partners first reported a position in HAE in Q1 2018 and held it in 2 quarters. The position peaked at $3K in Q3 2018. 279 funds tracked by Wall St. Rank hold HAE as of Q4 2018.

  • Avantax Planning Partners reported no remaining Haemonetics position as of Q4 2018 after selling out during the quarter.
  • Avantax Planning Partners sold 29 Haemonetics shares in Q4 2018, an estimated $3K.
  • Avantax Planning Partners first reported a position in Haemonetics in Q1 2018 and held it in 2 quarters.
  • Avantax Planning Partners's Haemonetics position peaked at $3K in Q3 2018.
  • 279 funds tracked by Wall St. Rank held Haemonetics as of Q4 2018.

Based on Avantax Planning Partners's 13F filing for Q4 2018, filed 14 Feb 2019.